Floatz logo

Irinotecan

Depression

National Cancer Institute (NCI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

73 Active assets in the Depression cohort.

Asset / SponsorPhaseRating
S-Ketamine
Chinese PLA General Hospital
Phase 4BBB
CITALOPRAM
Western University, Canada
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
VA Office of Research and Development
Phase 4BBB
Cipralex
Poznan University of Medical Sciences
Phase 4BBB
VENLOR
Janssen Research & Development, LLC
Phase 4BBB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →